3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
21
Leukemia, Myelomonocytic, Chronic
12
Myeloproliferative Disorders
4
Triple Negative Breast Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Anemia, Refractory, with Excess of Blasts
2
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Patient Preference
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
decitabine and cedazuridine drug combination
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn